Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“TROPION-Breast02 published in Annals of Oncology:
1L therapy with Dato-DXd led to near doubling of PFS, ORR and significant OS benefit (vs chemo) in IO-ineligible mTNBC. New important option and new hope for one of the most aggressive forms of breast cancer.”
Title: Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
Authors: R. Dent, Z. Shao, P. Schmid, J. Cortes, D.W. Cescon, S. Saji, K.H. Jung, T. Bachelot, S. Wang, E.M. Ramírez, G. Basaran, A. Stradella, R. Mathiba, S.-C. Chen, K. Shen, Á. Wéber, N. Battelli, N. Niikura, T. Luo, Y.S. Chae, N. Fischbach, G. Garbaos, A. Patera, K. Zhao, P. Vuković, M.J. Maxwell, T. Traina
Read the Full Article.
Other articles about breast cancer on OncoDaily.